+ 4.33
+ 1.27%
+ 2.11
+ 1.5%

PharmaDrug Dives Into DMT Research With The University Of Michigan

March 17, 2021 3:22 pm
Share to Linkedin Share to Twitter Share to Facebook Share to Print License More
PharmaDrug Dives Into DMT Research With The University Of Michigan

Pharmaceutical company PharmaDrug Inc. (OTC:LMLLF) — which focuses on cannabis, psychedelics and naturally-derived medicines — has launched a sponsored research agreement with the University of Michigan to study the psychedelic DMT.

The research will be led by Dr. Jimo Borjigin, in an effort to develop novel therapeutic strategies for DMT using animal models.

“I have a long history in studying DMT," said Dr. Jimo Borjigin. "I have dedicated my research in understanding how the brain functions and its effects on the heart in normal and abnormal states that can translate to relevant clinical uses.”  

A Pharma Focus on DMT: The company stated that it’s strategy around the pharmaceutical development of psychedelic therapies will revolve around the DMT molecule.

“Our research collaboration with the University of Michigan and its commitment on consciousness science is essential to our psychedelic pharmaceutical strategy of creating a unique portfolio of DMT therapies targeting rare disorders while also focusing on foundational research with DMT to explore and evaluate its therapeutic potential across all physiological areas of the human body,” said CEO Daniel Cohen.

Photo by Hans Reniers on Unsplash


For the latest in financial news, exclusive stories, memes follow Benzinga on Twitter, Facebook & Instagram. For the best interviews, stock market talk & videos, subscribe to our YouTube channel.

Related Articles

Psyched: MindMed Enters Psychedelics 2.0, Mind Cure Raises $18M, Mydecine Raises $13M

Mind Cure Closes $18M Raise Mind Cure Health Inc. (CSE:MCUR) recently announced the closing of a CA$23 Million ($18.1 million) offering. read more

Pharmadrug Dives Into Psychedelics, Buys Super Smart

Pharmadrug Inc. (CSE: BUZZ) (OTC: LMLLF) has agreed to acquire Super Smart, a Netherlands startup geared toward psychedelics. Terms of the deal were not disclosed. read more

Psyched: MindMed's Nasdaq Debut, PharmaDrug Gets Orphan Drug Designation For DMT, Numinus Launches Clinical Trial Of Naturally Derived Psilocybin

PharmaDrug Inc. (CSE: BUZZ) (Pink: LMLLF) announced an FDA-granted Orphan Drug Designation to its wholly owned subsidiary Sairiyo Therapeutics Inc., for the use of DMT in organ transplantations. read more

Psyched: Novamind Partners With Merck, Atai Expands To Japan, Australia Funds Psychedelics Research

Novamind Strikes Research Deal With Merck read more